Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma

Hepatobiliary and Pancreatic Diseases International

Volumn 12, Issue 2, 2013, Pages 171-179

  Yao, Min ^a   Yao, Deng Fu ^a   Bian, Yin Zhu ^a   Wu, Wei ^a   Yan, Xiao Di ^a   Yu, Dan Dan ^a   Qiu, Li Wei ^a   Yang, Jun Ling ^a   Zhang, Hai Jian ^a   Sai, Wen Li ^a   Chen, Jie ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Gene expression; Glypican 3; Hepatocellular carcinoma; Immunohistochemistry; Quantitative real time PCR; Sequencing

Indexed keywords

ALPHA FETOPROTEIN; GLYPICAN 3; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEPATITIS B; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84879251946     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-3872(13)60028-4     Document Type: Article

References (40)

1. Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 2010;7:448-458.
2. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008;134:1752-1763.
3. Anzola M. Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J Viral Hepat 2004;11:383-393.
4. Jain S, Singhal S, Lee P, Xu R. Molecular genetics of hepatocellular neoplasia. Am J Transl Res 2010;2:105-118.
5. Yao D, Jiang D, Huang Z, Lu J, Tao Q, Yu Z, et al. Abnormal expression of hepatoma specifc gamma-glutamyl transferase and alteration of gamma-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer 2000;88:761-769.
6. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008;48:2047-2063.
7. Yao DF, Dong ZZ, Yao M. Specifc molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2007;6:241-247.
8. Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004;127:S108-112.
9. Hayashi E, Kuramitsu Y, Okada F, Fujimoto M, Zhang X, Kobayashi M, et al. Proteomic profling for cancer progression: Differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines. Proteomics 2005;5:1024-1032.
10. Block TM, Marrero J, Gish RG, Sherman M, London WT, Srivastava S, et al. The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: notes from a recent workshop. Cancer Biomark 2008;4:19-33.
11. Wu W, Yao DF, Yuan YM, Fan JW, Lu XF, Li XH, et al. Combined serum hepatoma-specifc alpha-fetoprotein and circulating alpha-fetoprotein-mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2006;5:538-544.
12. Nouso K, Kobayashi Y, Nakamura S, Kobayashi S, Takayama H, Toshimori J, et al. Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein. J Gastroenterol Hepatol 2011;26:1195-1200.
13. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011;45:355-360.
14. Mao YL, Yang HY, Xu HF, Sang XT, Lu X, Yang ZY, et al. Signifcance of Golgi glycoprotein 73, a new tumor marker in diagnosis of hepatocellular carcinoma: a primary study. Zhonghua Yi Xue Za Zhi 2008;88:948-951.
15. Hu JS, Wu DW, Liang S, Miao XY. GP73, a resident Golgi glycoprotein, is sensibility and specifcity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med Oncol 2010;27:339-345.
16. Imbeaud S, Ladeiro Y, Zucman-Rossi J. Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma. Semin Liver Dis 2010;30:75-86.
17. Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res 2008;14:470-477.
18. Wang HL, Anatelli F, Zhai QJ, Adley B, Chuang ST, Yang XJ. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Arch Pathol Lab Med 2008;132:1723-1728.
19. Filmus J, Capurro M. The role of glypican-3 in the regulation of body size and cancer. Cell Cycle 2008;7:2787-2790.
20. Saleh HA, Aulicino M, Zaidi SY, Khan AZ, Masood S. Discriminating hepatocellular carcinoma from metastatic carcinoma on fne-needle aspiration biopsy of the liver: the utility of immunocytochemical panel. Diagn Cytopathol 2009;37:184-190.
21. Libbrecht L, Severi T, Cassiman D, Vander Borght S, Pirenne J, Nevens F, et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 2006;30:1405-1411.
22. Yao M, Yao DF, Bian YZ, Zhang CG, Qiu LW, Wu W, et al. Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2011;10:289-294.
23. Cheng W, Tseng CJ, Lin TT, Cheng I, Pan HW, Hsu HC, et al. Glypican-3-mediated oncogenesis involves the Insulinlike growth factor-signaling pathway. Carcinogenesis 2008;29:1319-1326.
24. The Liver Cancer Committee of Chinese Anticancer Association. Diagnostic criteria of primary hepatocellular carcinoma. Zhonghua Ganzangbing Zazhi 2001;9:324-325.
25. Qian J, Yao D, Dong Z, Wu W, Qiu L, Yao N, et al. Characteristics of hepatic igf-ii expression and monitored levels of circulating igf-ii mRNA in metastasis of hepatocellular carcinoma. Am J Clin Pathol 2010;134:799-806.
26. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312-1327.
27. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-346.
28. Pang RW, Joh JW, Johnson PJ, Monden M, Pawlik TM, Poon RT. Biology of hepatocellular carcinoma. Ann Surg Oncol 2008;15:962-971.
29. Tong A, Wu L, Lin Q, Lau QC, Zhao X, Li J, et al. Proteomic analysis of cellular protein alterations using a hepatitis B virus-producing cellular model. Proteomics 2008;8:2012-2023.
30. Filmus J, Capurro M. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn 2004;8:207-212.
31. Morford LA, Davis C, Jin L, Dobierzewska A, Peterson ML, Spear BT The oncofetal gene glypican 3 is regulated in the postnatal liver by zinc fngers and homeoboxes 2 and in the regenerating liver by alpha-fetoprotein regulator 2. Hepatology 2007;46:1541-1547.
32. Kwack MH, Choi BY, Sung YK. Cellular changes resulting from forced expression of glypican-3 in hepatocellular carcinoma cells. Mol Cells 2006;21:224-228.
33. Stigliano I, Puricelli L, Filmus J, Sogayar MC, Bal de Kier Joffé E, Peters MG. Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation. Breast Cancer Res Treat 2009;114:251-262.
34. Rehem RN, El-Shikh WM. Serum IGF-1, IGF-2 and IGFBP-3 as parameters in the assessment of liver dysfunction in patients with hepatic cirrhosis and in the diagnosis of hepatocellular carcinoma. Hepatogastroenterology 2011;58: 949-954.
35. Shafzadeh N, Ferrell LD, Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol 2008;21:1011-1018.
36. Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005;18:1591-1598.
37. Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005;65: 6245-6254.
38. Zhu ZW, Friess H, Wang L, Abou-Shady M, Zimmermann A, Lander AD, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001;48:558-564.
39. Nakano K, Orita T, Nezu J, Yoshino T, Ohizumi I, Sugimoto M, et al. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem Biophys Res Commun 2009;378:279-284.
40. Saffroy R, Pham P, Reffas M, Takka M, Lemoine A, Debuire New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med 2007;45:1169-179.